Helixmith Researcher Appeals... "NGENSIS Is a Great Pride, Requests Restraint from Spreading False Information"

[Asia Economy Reporter Jang Hyowon] Researchers at Helixmith have issued a statement requesting restraint from spreading distortions and false information regarding their main pipeline, Engensis (VM202).

On the 30th, Helixmith posted an appeal from the researchers at the Research and Development Center on the ‘IR Letter’ board of their website.

Helixmith is currently experiencing heightened conflict, with minority shareholders convening an extraordinary general meeting proposing the replacement of the current management. Moreover, false information and distorted claims about their key pipeline, Engensis, are spreading through online communities.

The researchers collectively stated in their appeal, “We have seen recent claims about Engensis that are factually incorrect and even distorted defamatory remarks,” adding, “We cannot stand by as continuous false claims undermine the efforts and achievements of the researchers, so we want to directly explain the research and development of Engensis.”

The researchers emphasized that Engensis was recognized for its uniqueness and was granted the special status of RMAT (Regenerative Medicine Advanced Therapy) by the U.S. FDA in 2018. They proudly noted that since 2017, only about 50 drugs have been designated as RMAT among approximately 20,000 to 40,000 clinical trials to date.

On the other hand, they mentioned that recently, some communities have been attacking Engensis with claims such as “no efficacy,” “clinical trial halted,” and “it's just a placebo.” The researchers said, “These groundless claims are disheartening to the researchers who are dedicating themselves to research and development, sacrificing sleep,” and added, “It is regrettable that even the existence of key research personnel is being denied.”

Helixmith explained that the research results of Engensis have been recognized through a rigorous peer-review process, and some have already produced Engensis-like products to evaluate efficacy and published papers. They argued that if there were no efficacy, neither the peer-review process would have been passed nor attempts to copy the product made.

Finally, the researchers stated, “We fully understand the difficult and painful feelings of the shareholders, but shaking the efforts of the research team with distorted information and false facts at this critical time benefits no one,” and added, “We are confident that the commercialization of Engensis is imminent and are doing our best to deliver a good treatment as soon as possible.”

Meanwhile, a company official said, “This is a voluntary collective action by the researchers to focus on research and development without disruption,” and requested, “We provide accurate information to shareholders through the fact-check board on the website, so we ask shareholders to verify the facts.”

This content was produced with the assistance of AI translation services.